You are here: Home » PTI Stories » National » News
Business Standard

Sun Pharma unveils first branded ophthalmic product in US

Press Trust of India  |  New Delhi 

Drug major Sun Pharma today launched BromSite solution, marked for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, in the US market.

The product will be marketed by Sun Ophthalmics, the company's branded ophthalmic business division, Sun Pharma said in a regulatory filing.



BromSite is the first branded product launched by the company in the US, following its focus on specialty business.

Approved by the US Food and Drug Administration (USFDA) on April 8, 2016, BromSite (bromfenac ophthalmic solution) 0.075% is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery.

Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility and absorption among others.

"As the first branded ophthalmic product launched by Sun Ophthalmics business division, BromSite's launch is a significant milestone for Sun Pharma in the US," Sun Pharma CEO - North America Business Abhay Gandhi said.

The company is confident that the product will prove itself a quality treatment option for cataract surgeons and their patients, he added.

"The BromSite launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service," Sun Ophthalmics Vice-President and Head Jerry St Peter said.

The stock today ended at Rs 713.80 on BSE, up 0.23 per cent, from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Sun Pharma unveils first branded ophthalmic product in US

Drug major Sun Pharma today launched BromSite solution, marked for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, in the US market. The product will be marketed by Sun Ophthalmics, the company's branded ophthalmic business division, Sun Pharma said in a regulatory filing. BromSite is the first branded product launched by the company in the US, following its focus on specialty business. Approved by the US Food and Drug Administration (USFDA) on April 8, 2016, BromSite (bromfenac ophthalmic solution) 0.075% is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery. Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility and absorption among others. "As the first branded ... Drug major Sun Pharma today launched BromSite solution, marked for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, in the US market.

The product will be marketed by Sun Ophthalmics, the company's branded ophthalmic business division, Sun Pharma said in a regulatory filing.

BromSite is the first branded product launched by the company in the US, following its focus on specialty business.

Approved by the US Food and Drug Administration (USFDA) on April 8, 2016, BromSite (bromfenac ophthalmic solution) 0.075% is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery.

Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility and absorption among others.

"As the first branded ophthalmic product launched by Sun Ophthalmics business division, BromSite's launch is a significant milestone for Sun Pharma in the US," Sun Pharma CEO - North America Business Abhay Gandhi said.

The company is confident that the product will prove itself a quality treatment option for cataract surgeons and their patients, he added.

"The BromSite launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service," Sun Ophthalmics Vice-President and Head Jerry St Peter said.

The stock today ended at Rs 713.80 on BSE, up 0.23 per cent, from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Sun Pharma unveils first branded ophthalmic product in US

Drug major Sun Pharma today launched BromSite solution, marked for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, in the US market.

The product will be marketed by Sun Ophthalmics, the company's branded ophthalmic business division, Sun Pharma said in a regulatory filing.

BromSite is the first branded product launched by the company in the US, following its focus on specialty business.

Approved by the US Food and Drug Administration (USFDA) on April 8, 2016, BromSite (bromfenac ophthalmic solution) 0.075% is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery.

Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility and absorption among others.

"As the first branded ophthalmic product launched by Sun Ophthalmics business division, BromSite's launch is a significant milestone for Sun Pharma in the US," Sun Pharma CEO - North America Business Abhay Gandhi said.

The company is confident that the product will prove itself a quality treatment option for cataract surgeons and their patients, he added.

"The BromSite launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service," Sun Ophthalmics Vice-President and Head Jerry St Peter said.

The stock today ended at Rs 713.80 on BSE, up 0.23 per cent, from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard